| Literature DB >> 32274169 |
Amrita Sukhavasi1, Thomas J O'Malley1, Elizabeth J Maynes1, Jae Hwan Choi1, Jonathan S Gordon1, Kevin Phan2, Vakhtang Tchantchaleishvili1.
Abstract
Patients with achondroplasia and other causes of dwarfism suffer from increased rates of cardiovascular disease relative to the remainder of the population. Few studies have examined these patients when undergoing cardiac surgery or percutaneous intervention. This systematic review examines the literature to determine outcomes following cardiac intervention in this unique population. An electronic search was performed in the English literature to identify all reports of achondroplasia, dwarfism, and cardiac intervention. Of the 5,274 articles identified, 14 articles with 14 cases met inclusion criteria. Patient-level data was extracted and analyzed. Median patient age was 55.5 [interquartile ranges (IQR), 43.8, 59.8] years, median height 102.0 [98.8, 112.5] cm, median BMI 32.1 [27.0, 45.9], and 57.1% (8/14) were male. Of these 14 patients, nine had the following documented skeletal abnormalities: 66.7% (6/9) had scoliosis, 66.7% (6/9) had kyphosis, 11.1% (1/9) had lordosis, 11.1% (1/9) pectus carinatum and 11.1% (1/9) spinal stenosis. Coronary artery disease was present in 53.8% (7/13), and 30.8% (4/13) patients previously suffered a myocardial infarction. Of the eight patients who underwent cardiac surgery, 37.5% (3/8) underwent multivessel coronary artery bypass grafting, 37.5% (3/8) underwent aortic valve replacement, 25.0% (2/8) underwent type A aortic dissection repair, and the remaining 12.5% (1/8) underwent pulmonary thromboendarterectomy. Six patients underwent percutaneous intervention. Median cardiopulmonary bypass time was 136.5 [110.0, 178.8] minutes. Median arterial cannula size was 20.0 [20.0, 24.0] Fr. Bicaval cannulation was performed in all cases describing cannulation strategy (5/5). Median superior vena cava cannula size was 28.0 [28.0, 28.0] Fr, and inferior vena cava cannula size was 28.0 [28.0, 28.0] Fr. No mortality was reported with a median follow up time of 6.0 [6.0, 10.5] months. In conclusion, Common cardiac procedures can be performed with reasonable safety in this patient population. Operative adjustments may need to be made with respect to equipment to accommodate patient-specific needs. 2020 Journal of Thoracic Disease. All rights reserved.Entities:
Keywords: Achondroplasia; cardiac intervention; cardiac surgery; dwarfism; outcomes
Year: 2020 PMID: 32274169 PMCID: PMC7139002 DOI: 10.21037/jtd.2020.02.05
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1PRISMA schematic diagram of the search strategy. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
Patient demographics
| Variable | Total (n=14) |
|---|---|
| Patient characteristics | |
| Age, median [IQR] | 55.5 [43.8, 59.8] |
| Male, % (n/N) | 57.1 (8/14) |
| Height (cm), median [IQR] | 102.0 [98.8, 112.5] |
| Weight (kg), median [IQR] | 40.5 [29.5, 45.6] |
| BSA (m2), median [IQR] | 1.1 [0.9, 1.2] |
| BMI (kg/m2), median [IQR] | 32.1 [27.0, 45.9] |
| No family history of achondroplasia, % (n/N) | 35.7 (5/14) |
| Skeletal abnormalities | |
| Scoliosis, % (n/N) | 66.7 (6/9) |
| Kyphosis, % (n/N) | 66.7 (6/9) |
| Lordosis, % (n/N) | 11.1 (1/9) |
| Pectus carinatum, % (n/N) | 11.1 (1/9) |
| Spinal stenosis, % (n/N) | 11.1 (1/9) |
| Medical history | |
| Hypertension, % (n/N) | 55.6 (5/9) |
| Hypercholesterolemia, % (n/N) | 55.6 (5/9) |
| Type 2 diabetes, % (n/N) | 22.2 (2/9) |
| Coronary artery disease, % (n/N) | 53.8 (7/13) |
| History of MI, % (n/N) | 30.8 (4/13) |
| Smoking history, % (n/N) | 50.0 (4/8) |
| History of transient ischemic attack, % (n/N) | 7.1 (1/14) |
| Obstructive sleep apnea, % (n/N) | 7.1 (1/14) |
BSA, body surface area; BMI, body mass index; MI, myocardial infarction; IQR, interquartile range.
Preoperative characteristics
| Variable | Total (n=14) |
|---|---|
| Ejection fraction % (n/N), median [IQR] | 50 [40, 60] |
| Coronary artery disease | 53.8 (7/13) |
| Right coronary artery stenosis, % (n/N) | 75.0 (6/8) |
| Left anterior descending stenosis, % (n/N) | 71.4 (5/7) |
| Circumflex stenosis, % (n/N) | 57.1 (4/7) |
| ST elevation, % (n/N) | 50.0 (3/6) |
| Aortic stenosis, % (n/N) | 21.4 (3/14) |
| Hypertrophic interventricular septum | 66.7 (2/3) |
| Interventricular septum size (mm), median [IQR] | 14.0 [13.5, 14.5] |
| Left ventricular hypertrophy, % (n/N) | 33.3 (1/3) |
| Maximum aortic valve transvalvular gradient (mmHg), median [IQR] | 114.5 [99.8, 129.2] |
| Aortic valve area (cm2), median [IQR] | 0.5 [0.5, 0.5] |
| Pulmonary stenosis, % (n/N) | 7.1 (1/14) |
| Mean pulmonary artery pressure (mmHg), median [IQR] | 45.0 [39.0, 51.5] |
| Preoperative atrial fibrillation, % (n/N) | 7.1 (1/14) |
IQR, interquartile range.
Intraoperative characteristics
| Variable | Total (n=14) |
|---|---|
| Surgery, % (n/N) | 57.1 (8/14) |
| Multivessel CABG, % (n/N) | 37.5 (3/8) |
| Aortic valve replacement, % (n/N) | 37.5 (3/8) |
| Type A aortic dissection repair, % (n/N) | 25.0 (2/8) |
| Pulmonary thromboendarterectomy, % (n/N) | 12.5 (1/8) |
| Percutaneous intervention, % (n/N) | 42.9 (6/14) |
| Percutaneous coronary intervention, % (n/N) | 66.7 (4/6) |
| Balloon aortic valvuloplasty and balloon pulmonary valvuloplasty, % (n/N) | 16.7 (1/6) |
| Micra transcatheter pacing system implantation, % (n/N) | 16.7 (1/6) |
| Intubation method | |
| Fiberoptic scope, % (n/N) | 33.3 (1/3) |
| Glidescope, % (n/N) | 33.3 (1/3) |
| Video laryngoscopy, % (n/N) | 33.3 (1/3) |
| Pediatric endotracheal tube, % (n/N) | 35.7 (5/14) |
| Cardiopulmonary bypass, % (n/N) | 100.0 (8/8) |
| Temperature | |
| Normothermia (>34 °C), % (n/N) | 25.0 (2/8) |
| Mild hypothermia (28.1–34 °C), % (n/N) | 12.5 (1/8) |
| Moderate hypothermia (20.1–28 °C), % (n/N) | 12.5 (1/8) |
| Deep hypothermia (14.1–20 °C), % (n/N) | 25.0 (2/8) |
| Circ arrest time (minutes), median [IQR] | 40.0 [29.5, 50.5] |
| CPB time (minutes), median [IQR] | 136.5 [110.0, 178.8] |
| Arterial cannulation site | |
| Aorta, % (n/N) | 60.0 (3/5) |
| Axillary, % (n/N) | 20.0 (1/5) |
| Femoral, % (n/N) | 20.0 (1/5) |
| Arterial cannula size (Fr), median [IQR] | 20.0 [20.0, 24.0] |
| Bicaval cannulation | 100.0 (5/5) |
| Superior vena cava cannula size (Fr), median [IQR] | 28.0 [28.0, 28.0] |
| Inferior vena cava cannula size (Fr), median [IQR] | 28.0 [28.0, 30.0] |
| Coronary artery bypass grafting | |
| Vein harvested | |
| Left saphenous, % (n/N) | 33.3 (1/3) |
| Right and left saphenous, % (n/N) | 33.3 (1/3) |
| Right saphenous, % (n/N) | 33.3 (1/3) |
| Vein quality | |
| Normal, % (n/N) | 66.7 (2/3) |
| Moderate, % (n/N) | 33.3 (1/3) |
| Artery harvested | |
| LIMA, % (n/N) | 66.7 (2/3) |
| LIMA and RIMA, % (n/N) | 33.3 (1/3) |
| Artery quality | |
| Normal, % (n/N) | 100.0 (2/2) |
| Aortic valve replacement | |
| Aortic cross clamp time (minutes), median [IQR] | 91.0 [67.5, 96.5] |
| Prosthetic valve type | |
| Carbomedics, % (n/N) | 33.3 (1/3) |
| Mechanical, bileaflet, % (n/N) | 33.3 (1/3) |
| Perceval S aortic valve, % (n/N) | 33.3 (1/3) |
| Aortic root size (mm), median [IQR] | 11.0 [10.5, 31.5] |
| Aortic root enlargement, % (n/N) | 33.3 (1/3) |
CABG, coronary artery bypass grafting; circ, circulation; CPB, cardio-pulmonary bypass; LIMA, left internal mammary artery; RIMA, right internal mammary artery; IQR, interquartile range.
Postoperative characteristics
| Variable | Total (n=14) |
|---|---|
| Time in ICU (days), median [IQR] | 2 [1, 5] |
| Number of postoperative days in hospital, median [IQR] | 7 [5, 15] |
| Postoperative aortic valve gradient (mmHg), median [IQR] | 11.0 [8.5, 13.5] |
| Postoperative complications | |
| VA ECMO, % (n/N) | 7.1 (1/14) |
| Mediastinal bleeding, % (n/N) | 7.1 (1/14)* |
| Pleural effusion, % (n/N) | 7.1 (1/14)* |
| Pneumothorax, % (n/N) | 7.1 (1/14)* |
| Pulmonary embolism, % (n/N) | 7.1 (1/14)* |
| Atrial fibrillation, % (n/N) | 7.1 (1/14) |
*, same patient who had undergone coronary artery bypass grafting. ICU, intensive care unit; IQR, interquartile range; VA ECMO, veno-arterial extracorporeal membrane oxygenation.
Outcomes
| Variable | Total (n=14) |
|---|---|
| Asymptomatic at discharge, % (n/N) | 100.0 (14/14) |
| Follow up time (months), median [IQR] | 6.0 [6.0, 10.5] |
| Asymptomatic at last follow up, % (n/N) | 100.0 (10/10) |
| 30-day mortality, % (n/N) | 0.0 (0/14) |
| Overall mortality, % (n/N) | 0.0 (0/14) |
IQR, interquartile range.